SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S, and the Assessments in Ankylosing Spondylitis Working Group. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997; 24: 22259.
  • 2
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 3
    Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N, and the Assessments in Ankylosing Spondylitis Working Group. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. J Rheumatol 1999; 26: 9514.
  • 4
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 5
    Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996; 35: 6671.
  • 6
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005; 64: 347.
  • 7
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 8
    Wells G, Anderson J, Boers M, Felson D, Heiberg T, Hewlett S, et al. MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. J Rheumatol 2003; 30: 11158.
  • 9
    Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 187686.
  • 10
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF α treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 143844.
  • 11
    Rudwaleit N, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major chemical response (BASDAI 50) to tumor necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 66570.
  • 12
    Tubach F, Dougados M, Falissard B, Baron G, Logeart I, Ravaud P. Feeling good rather than feeling better matters more to patients. Arthritis Rheum 2006; 55: 52630.
  • 13
    Boers M, Anderson JJ, Felson DT. Deriving an operational definition of low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 11124.
  • 14
    Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 11101.